Expression Analysis of the Imprinted Gene Transketolase-like 1 in Mouse and Human

Amy F. Friss

University of Connecticut - Storrs, amy.friss@gmail.com

Recommended Citation
https://opencommons.uconn.edu/gs_theses/90

This work is brought to you for free and open access by the University of Connecticut Graduate School at OpenCommons@UConn. It has been accepted for inclusion in Master's Theses by an authorized administrator of OpenCommons@UConn. For more information, please contact opencommons@uconn.edu.
Expression Analysis of the Imprinted Gene *Transketolase-like 1* in Mouse and Human

Amy Frances Friss
University of Connecticut

Abstract

Genomic imprinting is an epigenetic phenomenon resulting in differential gene expression based on parental origin. Recently, *transketolase-like 1 (TKTL1)* has been identified as an X-linked imprinted gene. TKTL1 functions in the nonoxidative branch of the pentose phosphate pathway (PPP), which maintains glutathione in a reduced state through the generation of NADPH. Previous studies on transaldolase, the other critical enzyme in the nonoxidative branch of the PPP, suggest that TKTL1 may affect the cell’s ability to reduce glutathione. This study provides evidence that *TKTL1* overexpression inhibits glutathione reduction. Intriguingly, aberrant glutathione levels are associated with autism. Additionally, studies involving Turner syndrome females found that differences in social behavior could distinguish females expressing the maternal X chromosome from those expressing the paternal X chromosome. This led researchers to hypothesize the influence of an X-linked imprinted gene in autism. Accordingly, this study compared *TKTL1* expression levels in autistic patients versus their unaffected siblings. The results suggest that further studies are required.
Expression Analysis of the Imprinted Gene *Transketolase-like 1* in Mouse and Human

Amy Frances Friss

B.S., University of Connecticut, 2009

A Thesis
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Science
At the
University of Connecticut
2011
Expression Analysis of the Imprinted Gene Transketolase-like 1 in Mouse and Human

Presented by

Amy Frances Friss, B. S.

Major Advisor

Michael O’Neill, Ph.D.

Associate Advisor

Rachel O’Neill, Ph.D.

Associate Advisor

Barbara Mellone, Ph.D.

University of Connecticut

2011
ACKNOWLEDGEMENTS

Thank you to everyone who has provided guidance and advice throughout my graduate studies. I would especially like to thank my advisor, Dr. Michael O’Neill, for allowing me the opportunity to join his lab as an undergraduate and continue on for my graduate research. My experiences in your lab have not only taught me how to perform techniques, but they have taught me the importance of ethical research and scientific integrity. I have learned more in your lab than I could have imagined. Thank you to my committee members, Dr. Rachel O’Neill and Dr. Barbara Mellone, for all of the help that you have provided and all that you have taught me.

I would like to thank Inga for training me and for being a wonderful mentor; what I have learned from you is invaluable. Thank you to Seth, Mike, Sohaib, Rob and Nate for always answering my questions and for helping me whenever I needed it. I would also like to thank Judy for providing assistance with my cell culture, it was an immense help. Thank you to everyone in Beach Hall for making graduate school a wonderful and unforgettable experience.

Thank you to my friends, my boyfriend J.R. and my family, all of whom have been very supportive and understanding. I would especially like to thank my dad and my sister. Dad, you have always been there for me and I appreciate it more than I can say. Tracey, my sister and my best friend, you have been there to listen to me, advise me and share my experiences with me. No words can express what this means to me. I would finally like to thank my mom; I know you are always watching over me and for that I am eternally grateful.
TABLE OF CONTENTS

Chapter 1: Background Information

1.1 Epigenetics and Imprinting

1.2 X-Linked Imprinting

1.3 Search for X-Linked Imprinted Genes

Chapter 2: TKTL1 Overexpression Studies

2.1 Background Information

Pentose Phosphate Pathway

Transketolase-like 1

2.2 Overexpression Studies

Construct Formation

Transfection

Western Blot Analysis

TKTL1 Expression Analysis

Glutathione Assay

Glutathione Assay Results

Glutathione Assay Analysis

NADPH Experiments

NADPH Assay Results

NADPH Assay Analysis

G6px Expression

G6px Expression Analysis
Chapter 1: Background Information

1.1 Epigenetics and Imprinting

Genomic imprinting is an epigenetic phenomenon resulting in parent-of-origin gene expression. Epigenetic mechanisms mediate genomic imprinting, leaving the DNA sequence unchanged. These mechanisms primarily include DNA methylation patterns and histone modifications. The epigenetic marking of an imprinted gene’s alleles designate their parental origin, allowing for appropriate expression patterns in the soma. Differential DNA methylation is the hallmark of imprinted genes. A differentially methylated region (DMR) is only methylated on one parental allele, typically on the cytosine of CpG dinucleotides. Often, DMRs constitute imprinting control regions (ICRs). The imprint is established in the germline and is maintained throughout genome-wide demethylation during preimplantation development. Deletion of an imprinted gene’s ICR can result in loss of imprinted gene expression or reversion to biallelic expression.

DNA methylation is regulated by DNA methyltransferases (DNMTs), which are classified as de novo methyltransferase or maintenance methyltransferase. DNMT3A and DNMT3B are the de novo methyltransferases, assisted by the DNMT3L protein. Though it is homologous to DNMT3A and DNMT3B, DNMT3L has no catalytic activity but is still a regulator of imprint establishment. Research demonstrated DNMT3L association with DNMT3A only in species in which imprinting occurs, suggesting that DNMT3L acquisition may have been related to the evolution of imprinting. Together, DNMT3A and DNMT3L are responsible for de novo methylation of most ICRs. Hemimethylated...
DNA is methylated by DNMT1, the enzyme necessary for maintaining DNA methylation at imprinted loci and across the genome.

Histones exhibit post-translational modifications including methylation and acetylation. Methylation of specific amino acid residues occurs via histone methyltransferase. Actively transcribing regions are typically methylated on arginine residues whereas methylation of lysine (K) residues is typically associated with repression, except for H3K4 trimethylation and H4K20 monomethylation which result in active transcription. Histones are acetylated or deacetylated using histone acetyltransferase (HAT) or histone deacetylase (HDAC), respectively. Upon acetylation, chromatin is transformed into a more relaxed structure that is associated with more actively transcribing DNA. The acetyl group carries a negative charge that interacts with the positively charged histones to create a neutral environment. A neutral environment decreases the histones’ interaction with the negatively charged DNA, providing greater accessibility for transcription factors.

Chromatin packages DNA into a structure that fits into the cell and is strong for support during mitosis and meiosis. Chromatin is composed of histone octamers, dimers of subunits H2A, H2B, H3 and H4, wrapped in DNA, forming a nucleosome. The different states of chromatin control gene expression and DNA replication: heterochromatin is associated with non-transcribing regions; euchromatin with actively transcribing regions.

Imprinted genes are generally found in 1Mb clusters controlled by one ICR. Clusters are typically regulated in one of two ways, including use of an insulator to control access to the shared regulatory elements of the cluster and silencing of the cluster
by noncoding RNA (ncRNA)\(^1\). The \(H19/Igf2\) locus is controlled by the insulator mechanism, while ncRNA regulates the \(Igf2r\) cluster in mouse\(^9\).

\(H19\) is a paternally imprinted (maternally expressed) gene on mouse chromosome 7, coding for a 2.2Kb non-coding RNA\(^10\). \textit{Insulin-like growth factor 2 (Igf2)} is a maternally imprinted (paternally expressed)\(^11,12\) gene influencing fetal growth and is found within the same cluster as \(H19\). Both genes share an enhancer\(^13\) and are controlled by the same ICR\(^14,15\). On the maternal allele the ICR binds CTCF, a protein that mediates insulator activity at the \(\beta\)-\textit{globin} locus\(^16\). CTCF binding blocks interaction of \(Igf2\) with the enhancers, while \(H19\) retains access and proceeds with transcription\(^17\). The ICR is methylated on the paternal allele, blocking CTCF binding and preventing \(H19\) from interacting with the enhancers while \(Igf2\) maintains interaction\(^9\) (Figure 1.1).

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Imprinted \(H19/Igf2\) cluster. Figure adapted from Bartolomei et al\(^1\).}
\end{figure}

More commonly, ncRNAs appear to regulate imprinting in clusters\(^18\), as in the \textit{insulin-like growth factor 2 receptor (Igf2r)} cluster on mouse chromosome 17A\(^19\) (Figure 1.2). The \(Igf2r\) cluster consists of maternally expressed genes \(Igf2r\), solute carrier 22a2 and 22a3 (\textit{Slc22a22} and \textit{Slc22a3}, respectively), paternally expressed antisense \(Igf2r\)
RNA (*Airn*) and a few non-imprinted genes. *Airn* is a 108 kb ncRNA that is arranged in an antisense orientation to *Igf2r*, with its promoter located in the cluster’s ICR. On the maternal chromosome the ICR is hypermethylated, preventing *Airn* transcription but allowing transcription of *Igf2r*, *Slc22a22* and *Slc22a3*. On the paternal copy, the ICR is unmethylated; however the *Igf2r* promoter is methylated after transcription initiation of the imprinted gene. *Igf2r* promoter methylation leads to transcription of *Airn* while the other 3 imprinted genes in the cluster are not transcribed. While it is known that *Airn* expression leads to gene silencing, the mechanism remains to be determined.

![Figure 1.2 Imprinted *Igf2r* cluster. Figure adapted from Bartolomei et al.](image)

1.2 X-Linked Imprinting

While most imprinted genes are found on autosomes, a subset has been identified on the X chromosome. Most X-linked genes, imprinted and non-imprinted, are subject to X chromosome inactivation in female mammals; one X chromosome in each cell is randomly inactivated as a form of dosage compensation to equate for the single (maternal) X chromosome in male cells. A counting mechanism ensures that each cell maintains only one active X chromosome per diploid cell. The inactive X chromosome is a Barr body and is visualized in somatic cells as compact chromatin.
X chromosome inactivation is mediated by the X chromosome inactivation center (XIC) which contains several elements that may play a role in inactivation. One such element is the X-chromosome-controlling element (XCE)\textsuperscript{22}. The X chromosome carrying the stronger XCE is more likely to remain active, leading to unequal X inactivation. Other elements include the genes XIST (X (inactive)-specific transcript)\textsuperscript{23} and TSIX (X (inactive)-specific transcript, antisense)\textsuperscript{24}. XIST encodes a 17 Kb noncoding RNA molecule that accumulates along the X chromosome containing the active XIST gene, resulting in inactivation of most genes on that chromosome with few exceptions. TSIX, also a noncoding transcript, is synthesized on the strand antisense to XIST and at the onset of X-inactivation extends along the entire XIST gene of the X chromosome destined to remain active. While it is known that TSIX regulates XIST expression \textit{in cis}, the mechanism by which this occurs is undetermined.

X chromosome inactivation complicates X-linked imprinting by influencing the expression level of X-linked imprinted genes in females. For example, a paternally imprinted gene will be expressed in approximately half of a female’s cells. The other half of cells with an inactive maternal X chromosome will have low, if any, expression of the paternally imprinted gene. In comparison, males will express this paternally imprinted gene from their single (maternal) X chromosome in every cell. Consequently, males will exhibit higher expression of this gene than females. The expression difference may contribute to sex-specific differences seen between males and females.
1.3 Search for X-Linked Imprinted Genes

A search for X-linked imprinted genes was performed using a mouse model for Turner syndrome (39,X\textsuperscript{m} and 39,X\textsuperscript{p})\textsuperscript{25}. The search led to the gene \textit{X-linked lymphocyte regulated (Xlr)} of which fifteen paralogs have been identified. Of these fifteen, three have been identified as imprinted genes: \textit{Xlr3b}, \textit{Xlr4b} and \textit{Xlr4c} are repressed on the paternal X chromosome\textsuperscript{25}. The \textit{Xlr3} and \textit{Xlr4} gene clusters are in a region of high homology that is highly conserved between mouse and human. In humans, this region is located near the end of Xq28, however no human homologs of any \textit{Xlr} gene have been identified. In addition, the function of Xlr proteins remains unclear.

Following identification of the imprinted mouse \textit{Xlr} genes, Dr. Addie May Nesbitt expanded the search for X-linked imprinted genes. Because imprinted genes are typically found in clusters, her search included four genes in a region 1 Mb downstream of the \textit{Xlr} locus and one gene 2 Mb upstream: \textit{Filamin alpha} or \textit{Actin binding protein 280/Abp280 (Flna)}, \textit{B cell receptor associated protein 31 (Bcap31)}, \textit{Inhibitor of kappa B kinase gamma (Ikbkg)}, \textit{Transketolase-like 1 (Tktl1)} and \textit{Cd99 antigen-like 2 or Xap89 (Cd99l2)}. All but one gene displayed biallelic expression in E9.5 embryo, E9.5 placenta and E14.5 liver. The exception was \textit{Tktl1} in liver, where there was a statistically significant difference between the different genotypes. 39,X\textsuperscript{m} \textit{Tktl1} expression was about 14-fold higher than 39,X\textsuperscript{p}, while 40,XX expression was in between 39,X\textsuperscript{m} and 39,X\textsuperscript{p} with the expression level closer to 39,X\textsuperscript{p}. Since X-linked imprinted genes have been implicated in neurocognitive disorders, a variety of brain subregions were assayed as well and analysis found increased \textit{Tktl1} expression in brain subregions of 39,X\textsuperscript{m}.

Subsequently, \textit{Tktl1} became the focus of X-linked imprinting studies.
Upon confirmation of Tktl1 imprinting in mice, the search for a human ortholog began. Human brain subregions from a 19 week 40,XX female indicate tissue specific imprinting of TKTL1. The hypothalamus, midbrain, frontal cortex and thalamus all displayed higher TKTL1 expression from one X chromosome while the temporal cortex did not show an imprint. Assays using human lymphoblastoid cells from Turner syndrome individuals demonstrated higher TKTL1 expression from the maternal X chromosome. Taken together, these results indicate that Tktl1/TKTL1 is paternally imprinted in both mouse and human.
CHAPTER 2: *TKTL1* Overexpression Studies

2.1 Background Information

**Pentose Phosphate Pathway**

Glucose metabolism in the cell occurs via two main biochemical pathways: the Embden-Meyerhof pathway and the pentose phosphate pathway (PPP). The Embden-Meyerhof pathway degrades glucose to provide lactic acid and ATP in anaerobic conditions. The PPP exists in the cytoplasm of the cell (Figure 2.1), producing the reducing equivalent NADPH (reduced nicotinamide adenine dinucleotide phosphate) and ribose for ribose nucleic acid. The PPP consists of two branches: the oxidative branch and the nonoxidative branch. The oxidative branch of the PPP is unidirectional, whereas the nonoxidative branch is fully reversible. NADPH is produced in the oxidative branch via the enzymes glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD). In the nonoxidative branch, the forward reactions produce glyceraldehyde-3-phosphate and fructose-6-phosphate while the reverse reactions produce ribose-5-phosphate.

Transaldolase (TAL) and Transketolase (TK) comprise the enzymes of the PPP’s nonoxidative branch. TAL catalyzes two reactions: glyceraldehydes-3-phosphate to fructose-6-phosphate; sedoheptulose-7-phosphate to erythrose-4-phosphate. TK catalyzes the following: xylulose-5-phosphate and ribose-5-phosphate to sedoheptulose-7-phosphate or glyceraldehydes-3-phosphate; xylulose-5-phosphate and erythrose-4-phosphate to glyceraldehydes-3-phosphate or fructose-6-phosphate. Conflicting results have been obtained as to which is the rate-limiting enzyme of this branch\textsuperscript{26,27,28,29}.
Figure 2.1 The pentose phosphate pathway of glucose metabolism. The oxidative branch begins at glucose-6-phosphate and produces ribulose-5-phosphate, which leads into the nonoxidative branch.
TK transfers a two carbon unit (1,2-dihydroxyethyl) in a two-substrate reversible reaction from ketose phosphates to aldose phosphates. TK is a thiamine-dependent transferase and therefore requires thiamine diphosphate, along with Ca$^{2+}$, as cofactors$^{30,26}$. The forward reactions catalyzed by TK produce glyceraldehyde-3-phosphate and fructose-6-phosphate which are utilized by glycolytic pathways or converted into glucose-6-phosphate and reintroduced into the PPP. In the reverse reaction, TK produces ribose-5-phosphate which is necessary for nucleic acid synthesis.

TK has been implicated in neurodegenerative diseases, diabetes and cancer$^{31}$. Thiamine deficiency in humans leads to the neuropsychiatric disorder Wernicke’s encephalopathy (WE), which is encountered in chronic alcoholics and patients with impaired nutrition associated with gastrointestinal disease or AIDS$^{32}$. In Alzheimer’s disease, varied TK proteins with different isoelectric points have been detected. Altered TK activity is not implicated in other neurological diseases, making this characteristic for Alzheimer’s disease and a potential biomarker$^{33}$. Diabetes patients have high blood glucose levels resulting in nonenzymatic glycation which causes vascular complications, neuropathy and retinopathy by producing advanced glycation end products$^{34}$. Treatment with vitamin B1 (thiamine derivative benfotiamine) supplements activates TK, blocking three major pathways of hyperglycemic damage$^{35}$. In cancer, some cells produce more than 85% of ribose for nucleic acid synthesis directly or indirectly from the nonoxidative branch of the PPP due to increased enzymatic activity$^{36}$. Specifically, transketolase-like 1 upregulation occurs in cancer cells$^{37}$, providing a novel target for cancer patient nutrition and treatment.
**Transketolase-like 1**

One transketolase gene, *transketolase (TK)*, and two transketolase-like genes, *transketolase-like 1 (TKTL1)* and *transketolase-like 2 (TKTL2)*, have been identified. *TKTL1*, initially described by Coy et al. in 1996 as a transketolase-related gene, contains a stop codon in a putative exon which causes deletion of that exon. The deletion mutates one of the two thiamine binding sites in the gene. Because of the pseudoexon it was thought that *TKTL1* was a pseudogene, however Coy et al. later demonstrated transketolase activity\(^\text{31}\). *TKTL1* encodes a tissue-specific spliced exon, causing formation of *TKTL1* transcripts which produce full length and smaller proteins and encode tissue-specific protein isoforms. While TKTL1 acts as a transketolase, it also has altered enzymatic activity. Coy et al. found that TKTL1 has broader substrate utilization than TK, as well as an enhanced one-substrate reaction\(^\text{31}\).

*TKTL1* is the sole transketolase upregulated in tumor cells, potentially due to its location; Xq28 is one of a few regions activated in malignancies and during the cell cycle\(^\text{39,40}\). Cancer cells naturally overexpressing *TKTL1* have an increased amount of reduced glutathione (GSH) and NADPH compared to similar cells in which *TKTL1* has been silenced with siRNA\(^\text{41}\). In cancer cells, upregulation of *TKTL1* is thought to increase flow through the oxidative branch of the PPP, leading to increased NADPH production and subsequently increased GSH production. The GSH increase would neutralize free radicals, characteristic of cancer cells, allowing the cancer cell to combat oxidative stress. Silencing *TKTL1*, however, causes the cancer cell to succumb to oxidative stress and apoptose.
2.2 Overexpression Studies

Functional analysis of *TKTL1* overexpression remains to be performed. Specifically, the effect of *TKTL1* overexpression on oxidative stress has not been studied. The effect of *TAL* overexpression, however, has been analyzed.

*TAL* overexpression in Jurkat human T cells leads to decreased enzymatic activities of G6PD and 6PGD and decreased NADPH and GSH levels\(^42\). Based on these results and others, Banki et al. proposed that TAL plays a critical role in regulating the balance between the oxidative and nonoxidative branches of the PPP\(^42\). I hypothesized that similar results would be obtained upon overexpression of *TKTL1*, coding for the other critical enzyme of the nonoxidative branch of the PPP.

I aimed to determine the effect of *TKTL1* overexpression on oxidative stress. Overall, I hypothesized that *TKTL1* overexpression would lead to increased cellular oxidative stress as measured by the effect of *TKTL1* overexpression on GSH levels.

NADPH and *G6pdx* expression levels were also analyzed in effort to determine *TKTL1*’s effect on the PPP. An immortalized mouse hippocampal cell line (HT-22, gift from the laboratory of Dr. Walikonis) was used for transfection. The HT-22 cell line is a glutamate-sensitive subclone from an HT-4 cell line. HT-4 cells were derived from mouse neuronal tissue immortalized with a temperature-sensitive SV40 T-antigen that adopted properties of differentiated neuronal cells at the nonpermissive temperature. *TKTL1* was overexpressed by transfecting HT-22 cells with the human *TKTL1* gene, allowing visualization of the resulting protein by Western blot analysis separately from the mouse protein based on antibody specificity and thus demonstrating *TKTL1* overexpression.
**Construct Formation**

pCAGGS (gift from the laboratory of Dr. LoTurco), a 4801bp plasmid with a constitutive chicken β-actin promoter allowing for constant expression, was used for transfection (Supplemental Figure 1). The human *TKTL1* sequence was inserted into the vector by restriction enzyme digestion and ligation (Protocol 1) and selected for in *Escherichia coli* by the ampicillin resistance cassette on pCAGGS.

**Transfection**

*TKTL1* was overexpressed in HT-22 cells by transfection using Lipofectamine™ LTX (Protocol 2). A GFP-pCAGGS construct (gift from the laboratory of Dr. Walikonis) was co-transfected with the hTktl1-pCAGGS construct in order to visualize transfection efficiency. Green fluorescent protein (GFP) was produced in the cells by the GFP-pCAGGS construct, presumably representing the transfection efficiency of hTktl1-pCAGGS as well. The images in Table 2.1, captured by an inverted microscope, illustrate the GFP expression and the confluency of HT-22 cells on the day they were harvested. There appears to be high transfection efficiency.
<table>
<thead>
<tr>
<th>Trial</th>
<th>Control</th>
<th>Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>3</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>4A</td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>4B</td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td>5A</td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
<tr>
<td></td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>---</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>5B</td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>6A</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>6B</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>7A</td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td>7B</td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
<tr>
<td>7C</td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
</tr>
<tr>
<td>Column</td>
<td>Designation</td>
<td>Image 1</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>9A</td>
<td></td>
<td><img src="image1" alt="Image" /></td>
</tr>
<tr>
<td>9B</td>
<td>NA</td>
<td><img src="image3" alt="Image" /></td>
</tr>
<tr>
<td>9C</td>
<td></td>
<td><img src="image5" alt="Image" /></td>
</tr>
<tr>
<td>9D</td>
<td></td>
<td><img src="image7" alt="Image" /></td>
</tr>
</tbody>
</table>

**Table 2.1** The first column contains the transfection trial designation. The second column contains images of HT-22 cells transfected with GFP-pCAGGS and pCAGGS (control). In the third column are images of HT-22 cells transfected with GFP-pCAGGS and hTktl1-pCAGGS (sample). Each box contains images of transfected HT-22 cells without visualizing the fluorescence on top and images showing the GFP expression on bottom, thereby indicating the expression of control or hTktl1-pCAGGS. “NA” means that images were not available for the indicated trials.
Western Blot Analysis

After the transfected HT-22 cells were harvested a Western blot was performed to confirm the absence and presence of human TKTL1 in control and sample cells, respectively (Protocol 3). Goat anti-human TKTL1 bound to TKTL1 in hTktt1-pCAGGS transfected cells, but not in control cells, confirming expression of human TKTL1 only in hTktt1-pCAGGS transfected cells (Table 2.2). Therefore, overexpression of *TKTL1* is indicated in cell samples and not controls.

<table>
<thead>
<tr>
<th>Trial</th>
<th>Western Blot Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><img src="image1.png" alt="Control Sample" /></td>
</tr>
<tr>
<td>2</td>
<td>NA</td>
</tr>
<tr>
<td>3</td>
<td><img src="image2.png" alt="Control Sample" /></td>
</tr>
<tr>
<td>4A</td>
<td><img src="image3.png" alt="Control Sample" /></td>
</tr>
<tr>
<td>4B</td>
<td><img src="image4.png" alt="Control Sample" /></td>
</tr>
<tr>
<td></td>
<td>Control</td>
</tr>
<tr>
<td>---</td>
<td>---------</td>
</tr>
<tr>
<td>5A</td>
<td><img src="5A.png" alt="Image" /></td>
</tr>
<tr>
<td>5B</td>
<td><img src="5B.png" alt="Image" /></td>
</tr>
<tr>
<td>6A</td>
<td><img src="6A.png" alt="Image" /></td>
</tr>
<tr>
<td>6B</td>
<td><img src="6B.png" alt="Image" /></td>
</tr>
<tr>
<td>7</td>
<td>Control A</td>
</tr>
<tr>
<td></td>
<td><img src="7.png" alt="Image" /></td>
</tr>
<tr>
<td>8</td>
<td>Control A*</td>
</tr>
<tr>
<td></td>
<td><img src="8.png" alt="Image" /></td>
</tr>
</tbody>
</table>

*Sample A spilled over into the well for Control A upon loading the gel. This control/sample pair was excluded from use in future assays.
Table 2.2 Detection of the human TKTL1 protein by Western blot in HT-22 cell lines after transfection with GFP-pCAGGS and control (pCAGGS) or hTktl1-pCAGGS (sample). The primary antibody was specific to human TKTL1 and the protein band size is 65kDa. Primary and secondary antibodies bound only to the sample transfected with hTktl1-pCAGGS. A negative control with secondary antibody only was performed with all controls and samples and resulted in a lack of protein bands (data not shown), demonstrating primary antibody specificity.

**TKTL1 Expression Analysis**

Primers were designed that captured both the mouse and human TKTL1 gene sequence (Supplemental Table 1), made possible by the high sequence homology shared by mouse and human TKTL1. Real-time RT-PCR was performed using the designed primers and RNA from control and hTktl1-pCAGGS transfected HT-22 cells (Protocols 4 and 5). The results demonstrate that TKTL1 gene expression is millions of times greater in hTktl1-pCAGGS transfected cells versus control cells (Figure 2.2); however there is no relation to the amount of TKTL1 protein in the cell samples. Since Western blot
analysis revealed human TKTL1 protein in only the hTktl1-pCAGGS transfected cells, it is reasonable to assume that total TKTL1 protein content is greater in the sample cells than the control cells. Therefore, TKTL1 is overexpressed in hTktl1-pCAGGS transfected cells compared to control cells.

**Figure 2.2** Real-time RT-PCR of TKTL1 in control and hTktl1-pCAGGS transfected HT-22 cells. TKTL1 transcription level increased by approximately 3 million fold in the hTktl1-pCAGGS transfected cells. The translation level of the gene is not reflected. Error bars indicate a 95% confidence interval.

**Glutathione Assay**

The Glutathione Assay kit from Cayman Chemical was used to determine the amounts of reduced and oxidized glutathione (GSH and GSSG, respectively) in control and hTktl1-pCAGGS transfected cells (Protocol 6). The kit relies on a colorimetric reaction where GSH reacts with 5,5’-dithio-bis-2-(nitrobenzoic acid) (DTNB) to produce 5-thio-2-nitrobenzoic acid (TNB), which has a yellow color. GSHTNB is concomitantly
produced and reduced by glutathione reductase to recycle the GSH and produce more TNB. The rate of TNB production is directly proportional to the GSHTNB to GSH reaction, which is directly proportional to the concentration of total glutathione. The absorbance of the yellow TNB at 405nm provides an estimation of total glutathione in a sample. In order to determine GSH amount alone, GSSG can be measured and subtracted from the total glutathione. Measurement of GSSG is performed similarly to total glutathione measurement, but with the addition of 2-vinylpyridine to the sample to derivatize glutathione. GSH and GSSG concentrations were calculated using the end point analysis method. Statistical methods were also used to analyze the data.

**Glutathione Assay Results**

Nine different HT-22 cell lines were assayed for GSH and GSSG, four of which resulted in negative amounts of GSSG in control and/or hTkt1-pCAGGS transfected cells. In other words, the absorbance values were less than the 0mM GSSG standard absorbance potentially due to negligible amounts of GSSG, insufficient cell concentration, or interference as suggested through communications with Cayman Chemical technical support. The cell samples were concentrated as much as possible and in some cases resulted in positive amounts of GSSG, while others remained negative.

Figure 2 displays the GSH/GSSG redox ratio for the five trials that resulted in positive concentrations. The ratio for trials 3, 6 and 8 decreased upon overexpression of \( TKTL1 \), while Trials 7 and 9 showed no difference. The GSH/GSSG ratios and standard deviations can be found in the supplemental information (Table 2).
Figure 2.3 GSH/GSSG in control and hTkt1-pCAGGS transfected HT-22 cells. These were the trials that resulted in positive concentration values. *TKTL1* overexpression resulted in decreased GSH/GSSG ratios or no difference. Error bars indicate a 95% confidence interval.

The raw absorbance values obtained for all nine glutathione assays were also analyzed. Initially, the proportion of GSH in each cell sample was calculated (Table 2.3 and Figure 2.4) using the formula \((\text{GSH} - \text{GSSG}) / \text{GSH}\). Since GSH in the assay represents total glutathione, the absorbance value for oxidized glutathione was subtracted from the GSH value to give the value for reduced GSH.
## GSH / Total Glutathione

<table>
<thead>
<tr>
<th>Trial #</th>
<th>Control</th>
<th>Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.21173</td>
<td>0.15589</td>
</tr>
<tr>
<td>2</td>
<td>0.71477</td>
<td>0.59042</td>
</tr>
<tr>
<td>3</td>
<td>0.57010</td>
<td>0.43391</td>
</tr>
<tr>
<td>4</td>
<td>0.75465</td>
<td>0.74759</td>
</tr>
<tr>
<td>5</td>
<td>0.78521</td>
<td>0.71819</td>
</tr>
<tr>
<td>6</td>
<td>0.47580</td>
<td>0.11955</td>
</tr>
<tr>
<td>7</td>
<td>0.11657</td>
<td>0.12729</td>
</tr>
<tr>
<td>8</td>
<td>0.60528</td>
<td>0.55941</td>
</tr>
<tr>
<td>9</td>
<td>0.38604</td>
<td>0.40499</td>
</tr>
</tbody>
</table>

**Table 2.3** Proportion of GSH in control and hTktl1-pCAGGS transfected cells.

![GSH / Total GSH](image)

**Figure 2.4** Proportion of GSH in control and hTktl1-pCAGGS transfected cells for all nine trials. Five trials resulted in a decreased proportion upon *TKTL1* overexpression, four trials displayed no change. Error bars indicate a 95% confidence interval.
A boxplot was then constructed to visualize the data (Figure 2.5). The boxplot illustrates that the proportion of GSH in HT-22 cells decreased upon TKTL1 overexpression. The decrease is statistically significant (P = 0.029) as determined by a one-tailed T-test.

![Boxplot of the proportion of GSH in control and hTktl1-pCAGGS transfected HT-22 cells using raw absorbance values (P= 0.029).](image)

**Figure 2.5** Boxplot of the proportion of GSH in control and hTktl1-pCAGGS transfected HT-22 cells using raw absorbance values (P= 0.029).
Glutathione Assay Analysis

Taken together, the analysis of the concentrations of GSH and GSSG in control and hTktl1-pCAGGS transfected cells and the analysis of the proportion of GSH in the cells based on raw absorbance values indicate that TKTL1 overexpression decreases the amount of GSH in the cell. Presumably, the cell would not be able to readily reduce free radicals, causing a state of oxidative stress. Based on the PPP, TKTL1 indirectly affects glutathione through influencing NADPH production. I hypothesized that NADPH will also be decreased, providing a mechanism which hinders GSH production.

NADPH Experiments

The NADP⁺/NADPH Assay kit from BioAssay was used to determine the ratio of NADPH/NADP⁺ in the control and hTktl1-pCAGGS transfected cells (Protocol 7). The kit has a procedure to extract NADP⁺ and NADPH from the cells using provided buffers. NADP⁺ and NADPH are then measured by a colorimetric reaction where formed NADPH reduces a formazan (MTT) reagent, which produces a color that is measured at 565nm. This color is proportionate to the NADP⁺/NADPH concentration in the sample.

NADPH Assay Results

Five different HT-22 cell lines were assayed for NADP⁺ and NADPH. Of the five, three displayed a decrease in the NADPH/NADP⁺ ratio upon TKTL1 overexpression, one increased and one resulted in no change (Figure 2.6). The NADPH and NADP⁺ concentrations and their ratio can be found in Supplemental Table 3.
Further analysis of NADPH/NADP⁺ is needed in order to provide a conclusive statement about the effect of TKTL1 overexpression on the NADPH/NADP⁺ ratio. The results suggest that there is an effect on the NADPH/NADP⁺ ratio since the ratio decreased in three out of five trials when TKTL1 was overexpressed. Since GSH was demonstrated to decrease, it was expected that NADPH would provide the same result. The hypothesized mechanism was that a decrease in NADPH would lead to a decrease in GSH, since NADPH reduces GSSG.

A decrease in the NADPH/NADP⁺ ratio would indicate that overexpression of TKTL1 decreases the amount of NADPH produced by the cell. Since increase, decrease and no change were all seen, it is possible that NADPH from other sources in the cell is skewing the result. A different assay may be needed to determine the effect of TKTL1.
overexpression on NADPH/NADP⁺, if any. Based on the Banki et al. paper, it is expected that NADPH will be affected.

**G6pdx Expression**

Real-time RT-PCR was performed to analyze *G6pdx* expression in control and hTkt1-pCAGGS transfected cells (Protocol 5). Analysis demonstrated a significant decrease of *G6pdx* when *TKTL1* was overexpressed (Figure 2.7).

![G6pdx Expression](image)

**Figure 2.7** Real-time RT-PCR of *G6pdx*, coding for G6PD in mouse, in control and hTkt1-pCAGGS transfected HT-22 cells. *G6pdx* levels significantly decreased upon *TKTL1* overexpression (P = 0.000135). Error bars indicate a 95% confidence interval.

**G6pdx Expression Analysis**

A decrease in *G6pdx* may lead to a decrease in NADPH production since *G6pdx* catalyzes the production of NADPH. Furthermore, less NADPH would be available in the cell to reduce GSSG to GSH, causing a decrease in GSH in the cell and leading to oxidative stress.
Discussion

*G6pdx* expression decreased due to overexpression of *TKTL1*. It was thought that this decrease would reduce the amount of NADPH produced in the cell. While the results point toward this effect, no conclusion can be made about the actual effect, if any, on NADPH. Assuming there were less NADPH available, the ability of the cell to reduce glutathione would be inhibited. The results demonstrate that the amount of GSH in the cell decreased in response to *TKTL1* overexpression. Based on this result, I determine that the cell is in a state of oxidative stress due to overexpression of *TKTL1*. To confirm this, direct analysis of reactive oxygen species (ROS) levels would be necessary. Increased ROS levels are expected based upon the results of this study and would support the conclusion of oxidative stress. The increase in ROS levels would also increase the cell’s sensitivity to apoptosis, which is measurable as well. This was the result upon *TAL* overexpression\(^4^2\) and I hypothesize the same effect for *TKTL1* overexpression. Therefore, future analysis may conclude that *TKTL1* levels in the cell play a role in programmed cell death.

ROS, including superoxide, hydroxyl, hydrogen peroxide, singlet oxygen and nitric oxide, cause cellular damage and maintain importance in autism\(^4^3\). Increased ROS levels have been found in patients with autism, as well as in other neuropsychiatric conditions\(^4^4\). Impairment in the cell’s antioxidant defense system may contribute to this increase. Patients with autism have a decreased amount of reduced GSH compared to unaffected individuals\(^4^5\) which decreases the cell’s capacity to reduce ROS and leads to oxidative stress. It is unclear, however, if oxidative stress contributes to the pathogenesis of autism, or if it is a secondary manifestation of the disorder\(^4^5\).
Chapter 3: Human Lymphoblast Autism Studies

3.1 Background Information

Autism

Autism is a neurodevelopmental syndrome with genetic and nongenetic causes, characterized by a variety of phenotypes. According to the Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR there are three criteria for diagnosing autism: impairment in 1) social interaction and 2) communication and 3) restricted patterns of behavior, interests and activities. If a patient has severe impairment in several criteria but not all, the DSM-IV-TR identifies the disorder as pervasive developmental disorder, or autism spectrum disorder (ASD) including autistic disorder, Rett’s Disorder, childhood disintegrative disorder, Asperger’s disorder, and pervasive developmental disorder not otherwise specified.

Nongenetic factors, such as oxidative stress, contribute to the pathogenesis of autism and several other neuropsychiatric disorders due to the brain’s vulnerability to oxidative stress\textsuperscript{46}. Research shows lowered levels of the antioxidant enzymes glutathione peroxidase and superoxide dismutase in autistic individuals, denoting impaired antioxidant defense mechanisms\textsuperscript{47}. Additionally, patients with autism displayed reduced levels of total glutathione and a lowered GSH/GSSG redox ratio\textsuperscript{48}. Supplementation with methyl B12 improved blood glutathione levels and the GSH/GSSG redox ratio in 30\% of test subjects, indicating methyl B12 as a potential beneficial autism treatment\textsuperscript{49}. Genetic and environmental effects may increase vulnerability to oxidative stress in autism.
Inconsistent linkage and association results\textsuperscript{50}, as well as low sibling recurrence compared to single-gene diseases\textsuperscript{51}, support the genetic complexity of autism. Multiple genetic loci on several chromosomes have been linked to autism or ASD\textsuperscript{52}. While some genes are directly linked to autism, others are thought to contribute indirectly by increasing an individual’s susceptibility to the disorder. The complex inheritance patterns formed by the combination of multiple genes that interact with each other and the environment remain unknown. Recently, de novo copy number variation mutations have been associated with a subset of ASD cases, typically of individuals with older fathers, leading researchers toward a new mode of inheritance\textsuperscript{53}. One example is the chromosomal region 15q11-q13\textsuperscript{54}. This region is an original region associated with autism and is also imprinted in Angelman and Prader-Willi syndromes (AS and PWS, respectively)\textsuperscript{55}. An imprint mutation causes either AS or PWS depending on parental mode of inheritance.

Several disorders are consistently associated with ASD, such as fragile X, Angelman and Prader-Willi syndromes, among others, however these cases account for only a small percentage of ASD diagnoses. Notably, all ASD-related syndromes are limited to the brain\textsuperscript{56}.

Genome-wide association studies (GWAS) are becoming increasingly important in the study of autism. GWAS have demonstrated that not only is rare variation important in autism, but common variation is as well. GWAS have identified regions and single nucleotide polymorphisms linked or associated with autism. The chromosomal region 15p14.1 is an example of a common variation region\textsuperscript{57}. Two genes previously connected to ASD, \textit{RyR2} and \textit{UPP2}, were also identified by GWAS as autism-associated genes\textsuperscript{58}. 
Autism is diagnosed four times as often in males as in females indicating involvement of an X-linked imprinted gene in autism\textsuperscript{59}. Turner syndrome studies by Skuse et al. point toward an X-linked gene that is paternally expressed\textsuperscript{60}.

**Turner Syndrome and Skuse Hypothesis**

Turner syndrome is characterized by complete or partial absence of one X chromosome in some or all of a female’s cell lines due to failed sex chromosome segregation. Turner individuals tend to have clinical problems, such as cardiovascular and kidney problems, and exhibit social behavior problems; however their intelligence is typically normal. Skuse et al. found that differences in social behavior could distinguish 45,X\textsuperscript{p} females from 45,X\textsuperscript{m} females\textsuperscript{60}. The study showed that 46,XX and 45,X\textsuperscript{p} females had superior social cognitive skills than 46,X\textsuperscript{m}Y males and 45,X\textsuperscript{m} females indicating that a gene expressed only from the paternal X chromosome is involved in social behavior\textsuperscript{60}. If an X-linked imprinted locus is responsible for social behavior differences this may explain why males tend to be affected more often than females by pervasive developmental disorders affecting social behavior, such as autism.

Researchers proposed that a maternal imprint on the X chromosome lowers the threshold for phenotypic expression of the genes predisposing an individual to autism\textsuperscript{61}. Particularly, this explains the male vulnerability to autism. Looking at this proposal another way, the imprint protects females from developing the disorder.

Another theory is the Baron-Cohen fetal testosterone exposure theory\textsuperscript{62}. Baron-Cohen proposed that fetal exposure to high androgen levels is associated with increased severity of some autistic traits, irrespective of sex chromosome constitution. He called
this the “extreme male brain.” The male brain type is defined as one that is superior in understanding physical objects over social common-sense; a female brain type is opposite of this. Individuals are assumed to fall within a continuum in regard to male and female brain types. Furthermore, an individual may be “cognitively balanced” where they show equal male and female brain types. Baron-Cohen suggested that autistic individuals have an extreme male brain type, regardless of sex. Depending on how extreme the male brain type is, an individual would fall on a continuum ranging from a touch of autism to classical autism. It remains controversial as to the neurobiological composition of a male versus female brain.

3.2 Human Lymphoblast Studies

As described previously, oxidative stress has been implicated in the pathogenesis of autism. My study indicates that TKTL1 overexpression increases oxidative stress, providing a potential connection to autism. Consequently, I aimed to determine if there is a higher level of TKTL1 expression in relation to autism.

Family studies were executed for comparison of TKTL1 expression levels in autistic individuals versus their unaffected siblings. Human lymphoblastoid cell lines were obtained from Rutgers University Cell and DNA Repository. The cell lines belonged to individuals affected with autism or ASD (as diagnosed by the DSM-IV) and their unaffected siblings.
**TKTL1 Expression Results**

The lymphoblastoid cell lines of siblings from six pedigrees were brought up in cell culture according to procedures provided by Rutgers University Cell and DNA Repository (Protocol 8). Total RNA was extracted from the obtained lymphoblastoidal cell pellets and was analyzed for *TKTL1* expression by real-time RT-PCR (Protocol 9). All real-time RT-PCR results are located in Supplemental Figures 2 through 8. The real-time RT-PCRs were repeated one or more times from the same total RNA.

The graphs in Figures 3.1 through 3.4 represent the autistic and unaffected males from the pedigrees that contained both types of males. We were more interested in comparing males to each other because of skewed X-inactivation patterns in female lymphoblastoid cell lines. Female lymphoblastoid cell lines tend to be mostly XiX or XXi, whereas male lymphoblastoid cell lines will always have an active maternal X chromosome. Since *TKTL1* is imprinted on the paternal X-chromosome, X-inactivation patterns in the cultured female lymphoblasts may therefore skew the *TKTL1* expression results.
Pedigree 72-0890

Figure 3.1 Real-time RT-PCR results for *TKTL1* expression in autistic and unaffected males for pedigree 72-0890. Error bars indicate a 95% confidence interval.

Pedigree 72-0890 displayed autistic male 03C23215 as having the highest *TKTL1* expression level. Following, autistic male 03C23216 and unaffected male 03C23218 had similar expression levels to each other. Unaffected male 03C23228 displayed the lowest *TKTL1* expression; however the 95% confidence interval was very large.
Figure 3.2 Real-time RT-PCR results for *TKTL1* expression in autistic and unaffected males for pedigree 74-0264. Error bars indicate a 95% confidence interval.

Unaffected male 03C16525 displayed the highest *TKTL1* expression level in pedigree 74-0264. The other unaffected male, 03C16522, had the lowest expression, while autistic male 03C16523 displayed an expression level in between the unaffected males, though closer to 03C16522.
Figure 3.3 Real-time RT-PCR results for TKTL1 expression in autistic and unaffected males for pedigree 61-3511. Error bars indicate a 95% confidence interval.

An autistic male (01C06845) again displayed the highest expression of TKTL1 in pedigree 63-3511. The other autistic male (01C06844) and the unaffected males (01C06843 and 01C06845) had expression levels similar to each other but lower than autistic male 01C06848.
Finally, pedigree 63-156 contained one unaffected male and one autistic male. They appear to similarly express $TKTL1$; however there may be a chance that male 01C07337 expresses $TKTL1$ at a higher level than autistic male 01C07335. The large error bars make this relationship difficult to determine.
**TKTL1 Expression Analysis**

It appears that autistic males may have approximately equal or higher TKTL1 expression than unaffected male siblings, with one exception. Autistic male 03C16523 in pedigree 74-0264 had lower expression than one of his unaffected brothers (03C16523).

The results for the males analyzed in the above four pedigrees were analyzed together and combined into autistic and control (unaffected) groups. Figure 3.5 displays the individuals’ TKTL1 expression levels along with their averaged expression. The two groups appear to have similar TKTL1 expression according to this analysis, with a fairly similar distribution of individual expression. A one-tailed T-test determined that there was no significant difference of TKTL1 expression between autistic and unaffected groups (P = 0.41417).

![Graph showing TKTL1 expression levels for autistic and control males](image)

**Figure 3.5** TKTL1 expression in autistic and control (unaffected) males from pedigrees 72-0890, 74-0264, 61-3511 and 63-156. Diamonds indicate individual expression levels for each male. Error bars indicate standard error.
An analysis of variance (ANOVA) was performed by Dr. Nathaniel Jue to further analyze the data. The results of the ANOVA are provided in Tables 3.1 and 3.2. The test indicates that there is no significant difference of *TKTL1* expression between autistic and unaffected individuals. Additionally, both autism (fixed factor) and family (random factor) have no significant effect on *TKTL1* expression.

<table>
<thead>
<tr>
<th>Source</th>
<th>DF</th>
<th>Sum of Squares</th>
<th>Mean Square</th>
<th>F Ratio</th>
<th>Prob &gt; F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model</td>
<td>4</td>
<td>16.888646</td>
<td>4.22216</td>
<td>0.7623</td>
<td></td>
</tr>
<tr>
<td>Error</td>
<td>8</td>
<td>44.309982</td>
<td>5.53875</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Total</td>
<td>12</td>
<td>77.814871</td>
<td>0.5782</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 3.1** Analysis of Variance.

<table>
<thead>
<tr>
<th>Source</th>
<th>Nparm</th>
<th>DF</th>
<th>DFDen</th>
<th>Sum of Squares</th>
<th>F Ratio</th>
<th>Prob &gt; F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autistic</td>
<td>1</td>
<td>1</td>
<td>8</td>
<td>0.20472</td>
<td>0.0368</td>
<td>0.8526</td>
</tr>
<tr>
<td>FamilyID &amp; Random</td>
<td>4</td>
<td>3</td>
<td>8</td>
<td>16.545622</td>
<td>0.9957</td>
<td>0.4428</td>
</tr>
</tbody>
</table>

**Table 3.2** Effects Tests.

**Discussion**

The information in Figure 3.5 and Tables 3.1 and 3.2 suggests that *TKTL1* expression differences do not exist between autistic and unaffected individuals. However, it must be taken into account that the sample size is relatively small. In total, thirteen males from four families were included in the above figure, which may not be representative of the larger population. The potential differences in *TKTL1* expression that are implicated in Figures 3.1 through 3.4 may also be misleading because of two
problems: real-time RT-PCR \( C_t \) values varied within triplicates for an individual and relative expression ratios varied for an individual between trials.

Observation of the \( C_t \) values for both \( GAPDH \) and \( TKTL1 \) revealed variation within the triplicates for a single individual. Variation could be attributed to poor primer design or old primers that degraded. Originally, polyA selected mRNA had been used for real-time RT-PCR, along with a different \( TKTL1 \) primer set. \( TKTL1 \) was difficult to amplify with these primers and produced poor melt curves. I discovered that the forward primer of that set had been designed to pick up a wild type SNP in the 5' UTR of \( TKTL1 \). With this knowledge, I decided that this was an unacceptable primer set to use and instead made a primer set spanning exons 4 and 5 of the gene. The new primer set amplified \( TKTL1 \) well from total RNA and the polyA mRNA selection was abandoned. For a period of time the \( C_t \) values had little variation within the triplicates, however within two months the \( C_t \) values started to vary. Since the \( GAPDH \) \( C_t \) values had not previously varied, I ordered the same primers again. Even with fresh primers the \( C_t \) values continued to vary within triplicates. Re-ordering the same \( GAPDH \) primers demonstrated that the variation was probably not due to degraded primers seeing as the issue persisted. It is also interesting to note that both sets of primers had previously amplified the genes well and consistently.

The variation of \( C_t \) values within the triplicates for a single individual and the occurrence of this happening for both primer sets caused two problems with the real-time RT-PCR results. First, many error bars on the graphs are very large, meaning that the 95% confidence intervals are very large. Repeating the real-time RT-PCRs did not fix this, however repetition caused the second problem to become apparent. Between trials
the relative expression of *TKTL1* among individuals changed even though the same RNA was used. For example, in pedigree 61-3511 on 3/30/11 autistic male 01C06844 displayed higher *TKTL1* expression than male 01C06848; however that relationship switched on 3/31/11 (Supplemental Figure 2.6). For this reason I took into account the data from all repetitions of pedigrees 61-3511 and 63-156 for the above analysis of unaffected males versus autistic males, however in actuality the relationships may be different. The data from only one trial each of pedigrees 72-0890 and 74-0264 was used for the above analysis because even larger error bars would have been introduced if more data was included. Again, the relationship between individuals may not be accurately represented.

While *GAPDH* has been used as a reference gene in many publications, 18S rRNA is less variable in expression level than *GAPDH* and therefore may be a better candidate for a reference gene. *GAPDH* mRNA levels are not constant and expression level variability was found in Epstein-Barr virus-transformed lymphoblastoid cell lines. Another possibility is that both primer sets were poorly designed and for an unknown reason were able to consistently amplify for some triplicates in earlier real-time RT-PCR's. Primer instability and degradation are also concerns. Fresh primer dilutions were made for each real-time RT-PCR, introducing freeze-thaw effects. Masters mixes were used whenever possible to prevent sample-to-sample and well-to-well variability; however automation of the sample preparation would reduce inconsistencies. It is also possible that the RNA degraded over time, possibly due to freeze-thawing the RNA on multiple occasions, or possible nuclease contamination. Variability could also be caused by lot-to-lot inconsistencies of reverse transcriptase and SYBR® Green.
An alternative explanation exists for the varied *TKTL1* expression between autistic and unaffected males between pedigrees. The variation could be due to an interaction between autism and family. *TKTL1* may be contributing to autism only in some families while in others it has little or no effect. The intersecting lines in the graph in Figure 3.6 demonstrate a potential interaction between autism and family. However, the interaction between a fixed and random variable cannot be tested for given the experimental design and statistical approach implemented in this study.

**Figure 3.6** Graph depicting the autistic and control mean relative *TKTL1* expression ratio in each family. FamilyIDs: 1 = 74-0264, 2 = 61-3511, 3 = 63-156, 4 = 72-0890.
Chapter 4: Synopsis

Oxidative stress has been implicated in the pathogenesis of autism. The pentose phosphate pathway is responsible for combating oxidative stress by reducing glutathione, which subsequently reduces free radicals. Previous studies have shown a decreased GSH/GSSG ratio and an increased free radical generation in lymphoblastoid cells of autistic and unaffected individuals\(^45\). Additionally, the amount of reduced glutathione in the cell is decreased when transaldolase is overexpressed\(^42\). Combined, there is reason to believe that \(TKTL1\) overexpression causes a decreased ability of the cell to reduce glutathione.

Overexpression of \(TKTL1\) in this study significantly decreased the GSH/GSSG ratio in the cell, indicating a heightened state of oxidative stress. It was thought that the NADPH/NADP\(^+\) ratio would decrease as well, however inconclusive results were obtained and further testing is required. \(G6pdx\) expression, however, did decrease upon \(TKTL1\) overexpression. The decrease of both the GSH/GSSG ratio and \(G6pdx\) expression lead me to hypothesize that the NADPH/NADP\(^+\) ratio actually decreases as well.

Skuse et al. suggested that an X-linked imprinted gene is involved in autism\(^60\), leading us to analyze autistic and unaffected individuals for \(TKTL1\) expression differences. It was thought that \(TKTL1\) expression may be higher in autistic individuals because of its apparent effect on oxidative stress; however no conclusive deduction could be made about \(TKTL1\) expression differences between individuals.

Potential autism susceptibility genes have been analyzed directly in brain tissue using real-time RT-PCR\(^66\). Since the brain is highly susceptible to the effects of oxidative stress, analysis of \(TKTL1\) expression in brain tissue would prove highly informative.
Chapter 5: Methods

Protocol 1: *TKTL1* Expression Construct Formation

The full-length human *TKTL1* CDS (Open Biosystems clone #4825931) was inserted into a pCAGGS vector (Supplemental Figure 1), which contains a chicken β-actin promoter. Both were digested with *Eco*RI and then ligated together with T4 DNA ligase as per standard methods. Successful construct formation was determined by *Bam*HI digest and DNA sequencing. The hTktl1 primers used for sequencing can be found in Supplemental Table 1.

Protocol 2: Expression of *TKTL1*

The *TKTL1* expression construct (hTktl1-pCAGGS) was co-transfected with GFP-pCAGGS into HT-22 cells, a mouse hippocampal cell line. T75 flasks were seeded with $1 \times 10^6$ cells in 10mL of media (DMEM, 10% FBS, 1% L-glutamine, 1% penicillin/streptomycin) and incubated overnight at 37°C, 5% CO$_2$. A transfection mix was then prepared with 750µl DMEM, 3µl Lipofectamine$^{TM}$ PLUS$^{TM}$ Reagent, 1µg GFP-pCAGGS and 1µg control (empty pCAGGS vector) or hTktl1-pCAGGS. This was incubated at room temperature for 5 minutes, then 9µl of Lipofectamine$^{TM}$ LTX was added and this was incubated at room temperature for 30 minutes. The transfection mix was added to the T75 flasks along with 3mL of media (DMEM, 10% FBS, 1% L-glutamine) and incubated for 5 hours at 37°C, 5% CO$_2$. The media was then changed to the antibiotic-containing media above. The cells were incubated for 3 days, with a media
change on day 2. On day 3 the cells were imaged and harvested. The cells were harvested in ice cold 1x PBS using a rubber policeman. Cell pellets were stored at -80°C.

**Protocol 3: Western Blot**

Western blot was performed using cell pellets and established protocols. The primary antibody was a monoclonal mouse anti-human TKTL1 antibody (Abcam®). The secondary antibody was stabilized Peroxidase Conjugated Goat anti-Mouse (H + L) (Thermo Scientific). After bloting, proteins were detected using Western Lightning® Plus-ECL (PerkinElmer).

**Protocol 4: Total RNA Extraction**

Total RNA was extracted from cell pellets using the RNeasy Mini Kit (QIAGEN) as per manufacturer’s instructions. The RNA was subsequently DNased using TURBO DNA-free™ (Ambion®).

**Protocol 5: Real-Time RT-PCR**

cDNA synthesis was performed with 1µg of RNA using a qScript cDNA Synthesis kit (Quanta BioSciences, Inc.) as per manufacturer’s protocol. Real-time RT-PCR was performed using PerfeCTa® SYBR® Green FastMix® for iQ (Quanta BioSciences, Inc.) and primers “AF TKTL1 F1” and “AF TKTL1 R1” for TKTL1/Tktl1, “G6pd F” and “G6pd R” for G6pdx, and “MF3” and “MR3” for mouse β-actin (Supplemental Table 1). The cycling conditions were as follows: 95°C for 3 min, 40 cycles of 95°C for 10 secs and 63.5°C (for TKTL1/Tktl1) or 63°C (for G6pdx) for 30 secs,
95°C for 1 min, 55°C for 1 min, 80 cycles of 55°C for 10 secs + 0.5°C/cycle.

Mathematical analysis of real-time RT-PCR data was carried out as described by normalizing and comparing $C_t$ values of the genes of interest to $\beta$-actin$^{67}$. 

**Protocol 6: Glutathione Assay**

Cell pellets were homogenized in the appropriate buffer and then deproteinated using metaphosphoric acid (Sigma-Aldrich®). Deproteinated samples were assayed with the Glutathione Assay Kit (Cayman Chemical). As per manufacturer’s instructions, total GSH was detected via a colorimetric reaction with DTNB. GSSG was detected by addition of 2-vinylpyridine (Sigma-Aldrich®) prior to assaying. A 96-well plate reader was used to measure the absorbance at 405nm at 5 minute intervals over a period of 30 minutes. The 25 minute read was used for the end-point analysis. End point analysis: 

\[
\text{[(sample absorbance – standard y-intercept) / (standard slope)] * 2.}
\]

All values were determined per manufacturer’s protocol.

**Protocol 7: NADP+/NADPH Assay**

Cell pellets were homogenized in provided buffers from the EnzyChrom™ NADP+/NADPH Assay Kit (BioAssay Systems). As per manufacturer’s protocol, NADP+ and NADPH were measured via a colorimetric reaction based on the ability of NADPH to reduce tetrazolium dye (MTT). A 96-well plate reader was used to measure the absorbance at 565nm at time “zero” and after a thirty minute incubation at room temperature. $\text{OD}_0$ was subtracted from $\text{OD}_{30}$ and the $\Delta$OD was used to calculate the NADP+ and NADPH concentrations using the standard curve.
Protocol 8: Human Lymphoblastoid Cell Culture

Human lymphoblastoid cell lines were received from Rutgers University Cell and DNA Repository at Rutgers, The State University of New Jersey, per NIMH permission. The cell lines consisted of lymphoblasts from individuals affected with autism or ASD (as diagnosed by the DSM-IV) and unaffected siblings. The cell lines were received as 1mL aliquots cryopreserved in 45% RPMI-1640, 50% FBS and 5% DMSO.

10mL of fresh media (88% RPMI-1640, 10% FBS, 1% penicillin/streptomycin and 1% nonessential amino acids) was added to T-75 flasks. The cell lines were thawed at 37˚C and pipetted into one flask each. 10mL of media was added to each flask 24 hours later. Fresh media was added as needed to maintain a cell density between 200,000 cells/mL and 500,000 cells/mL. Cells were collected as necessary.

When collected, the cell lines were either frozen down or stored as pellets. In both cases, the cell suspension was centrifuged at 1,000 x g for 5 minutes at 4˚C and then the media was removed. To freeze down, the cells were resuspended in freezing media (90% media from above and 10% DMSO) and 1mL aliquots were stored in cryotubes in liquid nitrogen. The cell pellets were stored at -80˚C.

Protocol 9: Human Lymphoblastoid Real-Time RT-PCR

Total RNA was extracted from the human lymphoblastoid cell pellets using TRIzol®. Subsequently cDNA was prepared as per manufacturer’s protocol (qScript™ cDNA Synthesis kit, Quanta BioSciences, Inc.™). Real-time PCR was performed using PerfeCTa® SYBR® Green FastMix® for iQ (Quanta BioSciences, Inc.™) as per usual methods using the primers “AF hTktl1 F14” and “AF hTktl1 R14” for TKTL1 and
“hGAPDH F” and “hGAPDH R” for GAPDH (Supplemental Table 1). The cycling conditions were as follows: 95°C for 3 min, 40 cycles of 95°C for 10 secs and 63°C for 30 secs, 95°C for 1 min, 55°C for 1 min, 80 cycles of 55°C for 10 secs + 0.5°C/cycle.

Mathematical analysis of the data was carried out as described by normalizing the $C_t$ values of TKTL1 to GAPDH and comparing the relative expression ratios$^{67}$. 
Chapter 6: Supplemental Information

Figure 1 pCAGGS vector map. Commercially available expression vector used for TKTL1 transfection into HT-22 cells. The TKTL1 CDS was inserted at the EcoRI sites. Image provided by the LoTurco laboratory.
Pedigree 72-0890

Relative Expression Ratio

Pedigree 72-0890 (4/15/11)

<table>
<thead>
<tr>
<th>Relative Expression Ratio</th>
<th>Female 03C23212</th>
<th>Autistic Female 03C23223</th>
<th>Male 03C23228</th>
<th>Autistic Male 03C23215</th>
<th>Autistic Male 03C23216</th>
<th>Male 03C23218</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>1.0000</td>
<td>1.4819</td>
<td>1.2068</td>
<td>1.5846</td>
<td>1.6172</td>
<td>1.5065</td>
</tr>
<tr>
<td>Autistic Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autistic Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 2 Two separate real-time RT-PCR trials of pedigree 72-0890. Error bars indicate a 95% confidence interval.
Pedigree 72-1650

Pedigree 72-1650 (3/28/11)

Relative Expression Ratio

- Female
- Autistic Male
- Autistic Male
- Autistic Spectrum Male
- Female
- Autistic Female

- 06C53575
- 06C53577
- 06C53574
- 06C53576
- 06C53572
- 06C53582
- 06C53583

- 72-1650-301
- 72-1650-302
- 72-1650-303
- 72-1650-304
- 72-1650-305
- 72-1650-306
- 72-1650-307
- 72-1650-308
- 72-1650-309

Relative Expression Values:
- Female 06C53575: 25.3144
- Autistic Male 06C53577: 13.0713
- Autistic Male 06C53574: 4.9610
- Autistic Spectrum Male 06C53576: 5.0858
- Female 06C53572: 1.1643
- Autistic Female 06C53582: 11.3049
- Autistic Female 06C53583: 54.9784
Figure 3 Two separate real-time RT-PCR trials for pedigree 72-1650. Error bars indicate a 95% confidence interval.
Figure 4 Real-time RT-PCR results for one trial of half of pedigree 74-0264. These individuals are cousins with the other half of this pedigree (shown below). Error bars indicate a 95% confidence interval.
Figure 5 Real-time RT-PCR results for two separate trials of half of pedigree 74-0264. These individuals are cousins with the other half of this pedigree (shown above). Error bars indicate a 95% confidence interval.
Pedigree 63-302

Pedigree 63-302 (3/31/11)

Relative Expression Ratio

- Autistic Male 01C05904: 1.2388 (95% CI: 0.9585, 1.6168)
- Autistic Female 01C05903: 1.8118 (95% CI: 1.5789, 2.0824)
- Autistic Female 01C05902: NA
- Autistic Male 01C05905: NA
**Figure 6** Real-time RT-PCR results for two separate trials of pedigree 63-302. Data was not available for Autistic Female 01C05902 and Autistic Male 01C05905. Error bars indicate a 95% confidence interval.
Pedigree 61-3511

```
00001  00002

1954  01C06846
      61-I-3511-001
1961  01C06847
      61-I-3511-002

00003  00004  00005  00007  00006

01C06843  01C06848  01C06844  01C06842  01C06845
61-I-3511-003  61-I-3511-004  61-I-3511-005  61-I-3511-007  61-I-3511-006
```

Pedigree 61-3511 (3/30/11)

```
Relative Expression Ratio

1.0421 ± 0.0000  1.2503 ± 0.0000  1.5860 ± 0.0000  1.0664 ± 0.0000  2.5100 ± 0.0000

Male 01C06843  Male 01C06848  Autistic Male 01C06844  Female 01C06842  Autistic Male 01C06845
```

Pedigree 61-3511 (3/31/11)

```
Relative Expression Ratio

1.1552 ± 0.0000  2.1924 ± 0.0000  1.0499 ± 0.0000  2.0670 ± 0.0000  3.3720 ± 0.0000

Male 01C06843  Male 01C06848  Autistic Male 01C06844  Female 01C06842  Autistic Male 01C06845
```
Figure 7 Real-time RT-PCR results for three separate trials of pedigree 61-3511. Error bars indicate a 95% confidence interval.
**Figure 8** Real-time RT-PCR results for two separate trials of pedigree 63-156. Data was not available for Female 01C07334 on 4/1/11. Error bars indicate a 95% confidence interval.
<table>
<thead>
<tr>
<th>Primer Name</th>
<th>Sequence (5'→ 3')</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>M13 F</td>
<td>CAGGAACACAGCTATGAC</td>
<td>Vector</td>
</tr>
<tr>
<td>M13 R</td>
<td>GTAAAAACGACGGCCAG</td>
<td>Vector</td>
</tr>
<tr>
<td>AF pCAGGS F4</td>
<td>TTCAGACTCCCAAAGGGGTTG</td>
<td>pCAGGS Vector</td>
</tr>
<tr>
<td>hTktl1 F7 (Operon)</td>
<td>ATGCCGAGAGAAGAGACAGA</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 F7 (Invitrogen)</td>
<td>GCATATGCAAGTACCGCTCT</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 F11</td>
<td>GAGGCGAGGGCTGAGTTC</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 R3</td>
<td>AAACATAAACACAGGGTAAGGAGGC</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 R5</td>
<td>TTCTGAGGACTCGACATCACTC</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 R10</td>
<td>TTCAATCCACATTTTTCTCTCTCATG</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 R13</td>
<td>GGCATCTGCTCTTTCTCTTCG</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 R15</td>
<td>AATTCTCGGACTTCCCCTAG</td>
<td>TKTL1</td>
</tr>
<tr>
<td>hTktl1 R16</td>
<td>CGGATCTCGAGCTCTGACTG</td>
<td>TKTL1</td>
</tr>
<tr>
<td>Actb MF3</td>
<td>ACACCCGCAAGGAGGATTGGC</td>
<td>β-Actin</td>
</tr>
<tr>
<td>Actb MR3</td>
<td>CGATGGAGGGGAATACAGGCC</td>
<td>β-Actin</td>
</tr>
<tr>
<td>AF TKTL1 F1</td>
<td>ATGTGCAACAGGATGGC</td>
<td>TKTL1/Tktl1</td>
</tr>
<tr>
<td>AF TKTL1 R1</td>
<td>TGGTCTGTATCTGGCTCTCAATTAA</td>
<td>TKTL1/Tktl1</td>
</tr>
<tr>
<td>G6pd F</td>
<td>AGCCTCCTATAAGCACCCTCAACAGCC</td>
<td>G6pdx</td>
</tr>
<tr>
<td>G6pd R</td>
<td>TCCAGCTGAGGTTCCAAGCC</td>
<td>G6pdx</td>
</tr>
<tr>
<td>hGAPDH F</td>
<td>AACTTTGGTGATCGTGAAAGG</td>
<td>GAPDH</td>
</tr>
<tr>
<td>hGAPDH R</td>
<td>ACAGCTTGCGACTGGGGACA</td>
<td>GAPDH</td>
</tr>
<tr>
<td>AF hTktl1 F14</td>
<td>TCTGTCTGGGAGGCATGGCC</td>
<td>TKTL1</td>
</tr>
<tr>
<td>AF hTktl1 R14</td>
<td>TCCCCGCGCCTCCACAACATAA</td>
<td>TKTL1</td>
</tr>
</tbody>
</table>

**Table 1** Name, sequence and gene for the primers used throughout the thesis.
<table>
<thead>
<tr>
<th>Trial #</th>
<th>Control/Sample</th>
<th>Average GSH/GSSG</th>
<th>Standard Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>2</td>
<td>Control</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>3</td>
<td>Control</td>
<td>7.32768</td>
<td>0.42949</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>2.82402</td>
<td>0.15848</td>
</tr>
<tr>
<td>4</td>
<td>Control</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>Control</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>6</td>
<td>Control</td>
<td>8.95068</td>
<td>1.23647</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>1.34007</td>
<td>0.12721</td>
</tr>
<tr>
<td>7</td>
<td>Control</td>
<td>1.23923</td>
<td>0.12119</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>1.27867</td>
<td>0.21110</td>
</tr>
<tr>
<td>8</td>
<td>Control</td>
<td>9.14736</td>
<td>0.25454</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>6.02062</td>
<td>0.21985</td>
</tr>
<tr>
<td>9</td>
<td>Control</td>
<td>3.49679</td>
<td>0.09919</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>3.36254</td>
<td>0.11754</td>
</tr>
</tbody>
</table>

**Table 2** Glutathione assay results. “NA” (Not Applicable) in the GSH/GSSG column means that the ratio could not be determined because the GSSG concentration was negative.

<table>
<thead>
<tr>
<th>Trial #</th>
<th>Control/Sample</th>
<th>Average NADPH/NADP+</th>
<th>Standard Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>0.67111</td>
<td>0.25864</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>0.90285</td>
<td>0.04089</td>
</tr>
<tr>
<td>2</td>
<td>Control</td>
<td>1.03492</td>
<td>0.19806</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>0.51953</td>
<td>0.06389</td>
</tr>
<tr>
<td>3</td>
<td>Control</td>
<td>5.37500</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>0.79070</td>
<td>NA</td>
</tr>
<tr>
<td>4</td>
<td>Control</td>
<td>0.62909</td>
<td>0.02542</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>0.46992</td>
<td>0.02570</td>
</tr>
<tr>
<td>5</td>
<td>Control</td>
<td>0.23906</td>
<td>0.02241</td>
</tr>
<tr>
<td></td>
<td>Sample</td>
<td>0.30233</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Table 3** NADP⁺/NADPH assay results. “NA” indicates that the standard deviation could not be calculated because only one sample in the triplicate provided usable data.
Chapter 7: References


